- NASDAQ: NVAX is trading at new record highs following a dramatic announcement.
- The US government has awarded Novavax $1.6 billion toward trialing and producing a coronavirus vaccine.
- Novavax may leapfrog its competition in the race against COVID-19.
Novavax Inc. (NASDAQ: NVAX) is trading at $107 in pre-market trading on Tuesday, up some 34% and above the 52-week high of $89.50. The Gaithersburg, Maryland-based firm that also operates in Sweden focuses on producing immunizations and has seen its stocks up some nearly 20 times from the 52-week low of $3.54 – before the most recent surge.
NVAX news
Novavax has been awarded a whopping $1.6 billion sum from the US federal government to develop and manufacture a COVID-19 vaccine candidate. The race to curb coronavirus continues at full force with Moderna, Oxford University, and other companies racing to find a cure.
The government investment is part of Washington's "Operation Warp Speed" project, intended to accelerate and discovering and distribution of a vaccine that would put COVID-19 to rest.
The funds will serve to fund the candidate coded NVX-CoV2373 including the Phase 3 trial and potentially to distribute them by late 2020 – an ambitious target. Nevertheless, the boost from the government may allow NASDAQ: NVAX to bypass the fierce competition.
Phase 1/2 consists of 130 healthy participants and was launched in Australia in May. Results are due out by late July. The third phase is larger, with 30,000 subjects.
Broader markets are set to open lower on Tuesday after surging on Monday. Cooling down in Asian markets and concerns ahead of new COVID-19 statistics from Florida, Texas, and other states are weighing on sentiment.
The US is recording around 50,000 cases per day, with the positive test rate and hospitalizations also on the rise. On the other hand, the death rate has been decline.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD extends recovery beyond 1.0400 amid Wall Street's turnaround
EUR/USD extends its recovery beyond 1.0400, helped by the better performance of Wall Street and softer-than-anticipated United States PCE inflation. Profit-taking ahead of the winter holidays also takes its toll.
GBP/USD nears 1.2600 on renewed USD weakness
GBP/USD extends its rebound from multi-month lows and approaches 1.2600. The US Dollar stays on the back foot after softer-than-expected PCE inflation data, helping the pair edge higher. Nevertheless, GBP/USD remains on track to end the week in negative territory.
Gold rises above $2,620 as US yields edge lower
Gold extends its daily rebound and trades above $2,620 on Friday. The benchmark 10-year US Treasury bond yield declines toward 4.5% following the PCE inflation data for November, helping XAU/USD stretch higher in the American session.
Bitcoin crashes to $96,000, altcoins bleed: Top trades for sidelined buyers
Bitcoin (BTC) slipped under the $100,000 milestone and touched the $96,000 level briefly on Friday, a sharp decline that has also hit hard prices of other altcoins and particularly meme coins.
Bank of England stays on hold, but a dovish front is building
Bank of England rates were maintained at 4.75% today, in line with expectations. However, the 6-3 vote split sent a moderately dovish signal to markets, prompting some dovish repricing and a weaker pound. We remain more dovish than market pricing for 2025.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.